Sage Journals: Discover world-class research

Abstract

Get full access to this article

View all access options for this article.

References

Schrand

Elliott

Ross

Bell

Mutnick

. A cost—benefit analysis of RSV prophylaxis in high-risk infants. Ann Pharmacother 2001; 35: 1186–93.

IMpact—RSV study group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102: 531–7.

PREVENT study group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 1997; 99: 93–9.

Wang

EEL

Tang

. Immunoglobulin for preventing respiratory syncytial virus infection. Cochrane Database Syst Rev 2000;CD001725.

Hall

. Medical progress: Respiratory syncytial virus and parainfluenza virus. N Engl J Med 2001; 344: 1917–28.

Comment: Prophylaxis for RSV Hospitalization May Not Be Cost-Saving

Abstract

Get full access to this article

References